Primary source: Ministry of Food and Drug Safety (MFDS)
The reporting and management requirements for adverse events of medical devices have been partially amended, potentially introducing new reporting criteria and electronic formats.
Manufacturers must ensure that their safety reporting systems adherently align with the updated regulations to maintain compliance and enhance post-marketing safety management practices.
Manufacturers and stakeholders in South Korea must review and update their safety reporting systems and Standard Operating Procedures (SOPs) to comply with the revised regulations.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Modernization of adverse event reporting criteria for medical devices; clarification of safety information management procedures; potential introduction of new electronic reporting formats or timelines for vigilance data submission.
The revision may introduce new criteria or updated electronic reporting methods for medical device vigilance. Manufacturers and stakeholders in the South Korean market must review these changes to ensure their safety reporting systems and SOPs are aligned with the updated post-marketing safety management framework.
Manufacturers and stakeholders in South Korea must review and update their safety reporting systems and Standard Operating Procedures (SOPs) to comply with the revised regulations.
The MFDS issued an administrative notice to update the Regulations on the Management of Safety Information such as Adverse Events of Medical Devices. This revision aims to modernize reporting criteria and clarify safety information management processes, potentially introducing new electronic reporting formats and timelines.
What changed: The reporting and management requirements for adverse events of medical devices have been partially amended, potentially introducing new reporting criteria and electronic formats.
Why it matters: Manufacturers must ensure that their safety reporting systems adherently align with the updated regulations to maintain compliance and enhance post-marketing safety management practices.
Practical implication: Manufacturers and stakeholders in South Korea must review and update their safety reporting systems and Standard Operating Procedures (SOPs) to comply with the revised regulations.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
